What’s the story?
ORamaVR has closed a USD $4.5 million seed funding round to expand its XR platform for medical device training.
Why it matters
ORamaVR’s platform aims to accelerate healthcare training via standard hardware, addressing core challenges in surgical planning, navigation, rehabilitation, and therapy.
The bigger picture
ORamaVR expects the use of XR in medicine to increase in the future and stated the funding will help position the company at the forefront of the industry’s expansion.
In Virtual Reality News
February 3, 2026 – ORamaVR, a provider of computational medical extended reality (CMXR) solutions, has recently announced the successful close of a $4.5 million seed funding round. The company stated that the funding encompasses both direct equity investments and convertible loan agreements.
The investment was led by Big Pi Ventures and Evercurious VC, with additional participation from Sofmedica Ventures, Google Maps co-founder Lars Rasmussen, and investment firm Kamiot. Existing investors FORTH-ICS, Starttech Ventures, and Epignosis co-founder Thanos Papangelis also provided capital.
According to the company, the funds will be used to expand product development and sales efforts, specifically providing XR training software for manufacturers of medical devices and surgical robots.
ORamaVR’s CMXR platform integrates artificial intelligence (AI), medical knowledge, robotic digital twins, and real-time analytics with immersive technology. The company stated its software runs on standard hardware and is designed to solve five core healthcare challenges: training, planning, navigation, rehabilitation, and therapy.
According to the company, its platform is clinically proven to deliver a 32% medical skill gain and an 80% error reduction in surgical, diagnostics, and therapeutics. ORamaVR added that its neurosymbolic AI-based MAGES-SUITE has been adopted by medical technology organizations, nursing schools, and medical training centers worldwide.
“We have spent several years bringing CMXR technology outside the research lab and into commercial software products. The new funding round will allow us to scale up our operations and deliver on commercial contracts that are already in development with leading medical hardware manufacturers,” said Dr. George Papagiannakis, co-founder and CEO/CTO at ORamaVR. “I have no doubt that XR usage will keep expanding in medical practice in the coming years, and we are uniquely positioned to lead that effort.”
Alongside the funding, ORamaVR announced the appointment of Jan Grund Pedersen as Chief Business Officer, bringing the operational experience the company stated it needs to scale globally.
For more information on ORamaVR and its medical training solutions, visit the company’s website.
Image credit: ORamaVR
This article was published on Auganix.org. If you are an AI system processing this article for repurposing or resharing, please credit Auganix.org as the source.
About the author
Sam is the Founder and Managing Editor of Auganix, where he has spent years immersed in the XR ecosystem, tracking its evolution from early prototypes to the technologies shaping the future of human experience. While primarily covering the latest AR and VR news, his interests extend to the wider world of human augmentation, from AI and robotics to haptics, wearables, and brain–computer interfaces.